Company news

Eupraxia Pharmaceuticals, Inc. news in 2026

Eupraxia Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day

October 22, 2026

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

October 15, 2026

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

October 9, 2026

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

September 30, 2026

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

September 8, 2026

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

August 13, 2026

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 11, 2026

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

July 13, 2026

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

July 7, 2026

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

June 19, 2026

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

May 12, 2026

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

May 6, 2026

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

May 5, 2026

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

May 1, 2026

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

April 22, 2026

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

April 21, 2026

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

April 13, 2026

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

March 17, 2026

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

March 12, 2026

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

February 20, 2026

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

February 19, 2026

Eupraxia Pharmaceuticals Announces Proposed Public Offering

February 18, 2026

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

January 8, 2026

Decks in 2026